# Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD)

> **NCT00730665** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 81 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** PF-00885706
- **DRUG:** Esomeprazole
- **DRUG:** PF-00885706
- **DRUG:** Esomeprazole
- **DRUG:** PF-00885706
- **DRUG:** Esomeprazole
- **DRUG:** PF-00885706
- **DRUG:** Esomeprazole
- **OTHER:** Placebo
- **DRUG:** Esomeprazole

## Key facts

- **NCT ID:** NCT00730665
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 81 (ACTUAL)
- **Why stopped:** This study has been placed on clinical hold by the sponsor due to operational reasons.
- **Last updated:** 2011-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00730665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00730665, "Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00730665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*